{"id":34941,"date":"2025-06-09T17:04:38","date_gmt":"2025-06-09T09:04:38","guid":{"rendered":"https:\/\/flcube.com\/?p=34941"},"modified":"2025-06-09T17:04:38","modified_gmt":"2025-06-09T09:04:38","slug":"burning-rock-reports-q1-2025-revenue-growth-and-rd-progress","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34941","title":{"rendered":"Burning Rock Reports Q1 2025 Revenue Growth and R&amp;D Progress"},"content":{"rendered":"\n<p>China-based medtech firm Burning Rock Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/BNR:NASDAQ\">NASDAQ: BNR<\/a>)\u00a0released its Q1 2025 financial report, showing a 5.9% year-over-year (YOY) increase in revenue to RMB 133.1 million (USD 18.5 million). R&amp;D expenses decreased by 38.8% YOY to RMB 40.4 million (USD 5.6 million), while the net loss narrowed significantly to RMB 13.5 million (USD 1.9 million) from RMB 121.5 million (USD 16.9 million) in Q1 2024. As of March 31, 2025, the company&#8217;s cash reserves stood at RMB 497.4 million (USD 69.2 million).<\/p>\n\n\n\n<p><strong>Business Segment Performance<\/strong><br>In-hospital testing revenue grew 0.5% YOY to RMB 57.7 million (USD 8 million), supported by stable sales volume. Central laboratory business revenue declined by 19.6% YOY to RMB 38.3 million (USD 5.3 million), in line with the company\u2019s strategic shift toward in-hospital diagnostics. Pharma research and development services recorded a significant 79.9% YOY increase in revenue to RMB 37.1 million (USD 5.2 million), driven by increased development and testing services and milestone achievements in multiple drug development projects.<\/p>\n\n\n\n<p><strong>Clinical Research Advancements<\/strong><br>During the reporting period, Burning Rock continued to advance its clinical research in circulating tumor DNA (ctDNA) monitoring and minimal residual disease (MRD) detection. The company presented multiple study findings at the 2025 ASCO and AACR conferences, highlighting its commitment to innovation in cancer diagnostics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based medtech firm Burning Rock Ltd (NASDAQ: BNR)\u00a0released its Q1 2025 financial report, showing a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":34942,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[724,27,1108],"class_list":["post-34941","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-burning-rock","tag-finanical-reports","tag-nasdaq-bnr"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Burning Rock Reports Q1 2025 Revenue Growth and R&amp;D Progress - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based medtech firm Burning Rock Ltd (NASDAQ: BNR)\u00a0released its Q1 2025 financial report, showing a 5.9% year-over-year (YOY) increase in revenue to RMB 133.1 million (USD 18.5 million). R&amp;D expenses decreased by 38.8% YOY to RMB 40.4 million (USD 5.6 million), while the net loss narrowed significantly to RMB 13.5 million (USD 1.9 million) from RMB 121.5 million (USD 16.9 million) in Q1 2024. As of March 31, 2025, the company&#039;s cash reserves stood at RMB 497.4 million (USD 69.2 million).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34941\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Burning Rock Reports Q1 2025 Revenue Growth and R&amp;D Progress\" \/>\n<meta property=\"og:description\" content=\"China-based medtech firm Burning Rock Ltd (NASDAQ: BNR)\u00a0released its Q1 2025 financial report, showing a 5.9% year-over-year (YOY) increase in revenue to RMB 133.1 million (USD 18.5 million). R&amp;D expenses decreased by 38.8% YOY to RMB 40.4 million (USD 5.6 million), while the net loss narrowed significantly to RMB 13.5 million (USD 1.9 million) from RMB 121.5 million (USD 16.9 million) in Q1 2024. As of March 31, 2025, the company&#039;s cash reserves stood at RMB 497.4 million (USD 69.2 million).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34941\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-09T09:04:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0911.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34941#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34941\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Burning Rock Reports Q1 2025 Revenue Growth and R&amp;D Progress\",\"datePublished\":\"2025-06-09T09:04:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34941\"},\"wordCount\":204,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34941#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0911.webp\",\"keywords\":[\"Burning Rock\",\"Finanical Reports\",\"NASDAQ: BNR\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34941#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34941\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34941\",\"name\":\"Burning Rock Reports Q1 2025 Revenue Growth and R&amp;D Progress - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34941#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34941#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0911.webp\",\"datePublished\":\"2025-06-09T09:04:38+00:00\",\"description\":\"China-based medtech firm Burning Rock Ltd (NASDAQ: BNR)\u00a0released its Q1 2025 financial report, showing a 5.9% year-over-year (YOY) increase in revenue to RMB 133.1 million (USD 18.5 million). R&D expenses decreased by 38.8% YOY to RMB 40.4 million (USD 5.6 million), while the net loss narrowed significantly to RMB 13.5 million (USD 1.9 million) from RMB 121.5 million (USD 16.9 million) in Q1 2024. As of March 31, 2025, the company's cash reserves stood at RMB 497.4 million (USD 69.2 million).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34941#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34941\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34941#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0911.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0911.webp\",\"width\":1080,\"height\":608,\"caption\":\"Burning Rock Reports Q1 2025 Revenue Growth and R&D Progress\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34941#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Burning Rock Reports Q1 2025 Revenue Growth and R&amp;D Progress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Burning Rock Reports Q1 2025 Revenue Growth and R&amp;D Progress - Insight, China&#039;s Pharmaceutical Industry","description":"China-based medtech firm Burning Rock Ltd (NASDAQ: BNR)\u00a0released its Q1 2025 financial report, showing a 5.9% year-over-year (YOY) increase in revenue to RMB 133.1 million (USD 18.5 million). R&D expenses decreased by 38.8% YOY to RMB 40.4 million (USD 5.6 million), while the net loss narrowed significantly to RMB 13.5 million (USD 1.9 million) from RMB 121.5 million (USD 16.9 million) in Q1 2024. As of March 31, 2025, the company's cash reserves stood at RMB 497.4 million (USD 69.2 million).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34941","og_locale":"en_US","og_type":"article","og_title":"Burning Rock Reports Q1 2025 Revenue Growth and R&amp;D Progress","og_description":"China-based medtech firm Burning Rock Ltd (NASDAQ: BNR)\u00a0released its Q1 2025 financial report, showing a 5.9% year-over-year (YOY) increase in revenue to RMB 133.1 million (USD 18.5 million). R&D expenses decreased by 38.8% YOY to RMB 40.4 million (USD 5.6 million), while the net loss narrowed significantly to RMB 13.5 million (USD 1.9 million) from RMB 121.5 million (USD 16.9 million) in Q1 2024. As of March 31, 2025, the company's cash reserves stood at RMB 497.4 million (USD 69.2 million).","og_url":"https:\/\/flcube.com\/?p=34941","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-09T09:04:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0911.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34941#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34941"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Burning Rock Reports Q1 2025 Revenue Growth and R&amp;D Progress","datePublished":"2025-06-09T09:04:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34941"},"wordCount":204,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34941#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0911.webp","keywords":["Burning Rock","Finanical Reports","NASDAQ: BNR"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34941#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34941","url":"https:\/\/flcube.com\/?p=34941","name":"Burning Rock Reports Q1 2025 Revenue Growth and R&amp;D Progress - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34941#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34941#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0911.webp","datePublished":"2025-06-09T09:04:38+00:00","description":"China-based medtech firm Burning Rock Ltd (NASDAQ: BNR)\u00a0released its Q1 2025 financial report, showing a 5.9% year-over-year (YOY) increase in revenue to RMB 133.1 million (USD 18.5 million). R&D expenses decreased by 38.8% YOY to RMB 40.4 million (USD 5.6 million), while the net loss narrowed significantly to RMB 13.5 million (USD 1.9 million) from RMB 121.5 million (USD 16.9 million) in Q1 2024. As of March 31, 2025, the company's cash reserves stood at RMB 497.4 million (USD 69.2 million).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34941#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34941"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34941#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0911.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0911.webp","width":1080,"height":608,"caption":"Burning Rock Reports Q1 2025 Revenue Growth and R&D Progress"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34941#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Burning Rock Reports Q1 2025 Revenue Growth and R&amp;D Progress"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0911.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34941","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34941"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34941\/revisions"}],"predecessor-version":[{"id":34943,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34941\/revisions\/34943"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34942"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34941"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34941"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}